Form 4: Arcellx Chief Medical Officer Christopher Heery Reports Stock Transactions
SEC Form 4
Christopher Heery, Chief Medical Officer of Arcellx, Inc., reports the acquisition and disposal of common stock and derivative securities, including stock options, on August 1, 2024.
Summary
- On August 1, 2024, Christopher Heery, the Chief Medical Officer of Arcellx, Inc., engaged in transactions involving the company's stock.
- He exercised stock options to acquire 9,316 shares at $6.28 and 10,684 shares at $15.
- He also sold 19,268 shares at a weighted average price of $60.3949 and 732 shares at a weighted average price of $61.128.
- Following these transactions, Heery directly owns 10,010 shares of common stock and holds options for 54,505 shares at $6.28 and 179,521 shares at $15.
- The sale of shares was executed under a pre-arranged Rule 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions without indicating positive or negative implications for the company's performance.
Positives
- The reporting person's transactions are in compliance with Rule 10b5-1, suggesting a planned and transparent approach to stock sales.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Insider trading activity is a common occurrence in publicly listed biotechnology companies like Arcellx.
- Similar filings are regularly made by executives at companies such as Gilead Sciences, Amgen, and Biogen.
- The use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of illegal insider trading.
Stakeholder Impact
- The transactions may have a minor impact on shareholders as they reflect insider trading activity, but the use of a Rule 10b5-1 plan mitigates concerns about opportunistic trading.
Key Dates
| Date | Description |
|---|---|
| 2021-04-26 | Vesting Commencement Date for shares issued pursuant to the Issuer's 2017 Equity Incentive Plan |
| 2022-02-03 | Equity Grant Date for shares issued pursuant to the Issuer's 2022 Equity Incentive Plan |
| 2023-12-22 | Date of Rule 10b5-1 trading plan entered into by the Reporting Person |
| 2024-08-01 | Date of transaction |
| 2024-08-02 | Date of signature |
| 2031-06-09 | Expiration Date for Stock Option (right to buy) at $6.28 |
| 2032-02-03 | Expiration Date for Stock Option (right to buy) at $15 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.